Efficacy as a vector: the relative prevalence and paucity of inverse agonism
- PMID: 14722230
- DOI: 10.1124/mol.65.1.2
Efficacy as a vector: the relative prevalence and paucity of inverse agonism
Abstract
This article describes the expected phenotypic behavior of all types of ligands in constitutively active receptor systems and, in particular, the molecular mechanisms of inverse agonism. The possible physiological relevance of inverse agonism also is discussed. Competitive antagonists with the molecular property of negative efficacy demonstrate inverse agonism in constitutively active receptor systems. This is a phenotypic behavior that can only be observed in the appropriate assay; a lack of observed inverse agonism is evidence that the ligand does not possess negative efficacy only if it can be shown that constitutive receptor activity is present. In the absence of constitutive activity, inverse agonists behave as simple competitive antagonists. A survey of 105 articles on the activity of 380 antagonists on 73 biological G-protein-coupled receptor targets indicates that, in this sample dataset, 322 are inverse agonists and 58 (15%) are neutral antagonists. The predominance of inverse agonism agrees with theoretical predictions which indicate that neutral antagonists are the minority species in pharmacological space.
Similar articles
-
Structural requirements for inverse agonism and neutral antagonism of indole-, benzimidazole-, and thienopyrrole-derived histamine H4 receptor ligands.J Pharmacol Exp Ther. 2010 Aug;334(2):513-21. doi: 10.1124/jpet.110.165977. Epub 2010 May 18. J Pharmacol Exp Ther. 2010. PMID: 20484153
-
Inverse agonism or neutral antagonism at G-protein coupled receptors: a medicinal chemistry challenge worth pursuing?Eur J Pharmacol. 2006 Dec 28;553(1-3):1-9. doi: 10.1016/j.ejphar.2006.09.032. Epub 2006 Sep 26. Eur J Pharmacol. 2006. PMID: 17081515 Review.
-
Constitutive activity and inverse agonism at the alpha1adrenoceptors.Biochem Pharmacol. 2007 Apr 15;73(8):1076-83. doi: 10.1016/j.bcp.2006.10.024. Epub 2006 Nov 27. Biochem Pharmacol. 2007. PMID: 17125741 Review.
-
Inverse agonism at serotonin and cannabinoid receptors.Prog Mol Biol Transl Sci. 2010;91:1-40. doi: 10.1016/S1877-1173(10)91001-6. Prog Mol Biol Transl Sci. 2010. PMID: 20691957 Review.
-
Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors.Pharmacol Ther. 2009 Feb;121(2):160-73. doi: 10.1016/j.pharmthera.2008.10.010. Epub 2008 Dec 6. Pharmacol Ther. 2009. PMID: 19109993 Review.
Cited by
-
Gaddum Memorial Lecture 2014: receptors as an evolving concept: from switches to biased microprocessors.Br J Pharmacol. 2015 Sep;172(17):4238-53. doi: 10.1111/bph.13217. Epub 2015 Jul 21. Br J Pharmacol. 2015. PMID: 26075971 Free PMC article. Review.
-
Some implications of receptor theory for in vivo assessment of agonists, antagonists and inverse agonists.Biochem Pharmacol. 2006 Jun 14;71(12):1663-70. doi: 10.1016/j.bcp.2005.12.038. Epub 2006 Feb 7. Biochem Pharmacol. 2006. PMID: 16460689 Free PMC article.
-
Reanalysis of constitutively active rat and human 5-HT7(a) receptors in HEK-293F cells demonstrates lack of silent properties for reported neutral antagonists.Naunyn Schmiedebergs Arch Pharmacol. 2006 Oct;374(1):31-9. doi: 10.1007/s00210-006-0093-y. Epub 2006 Sep 12. Naunyn Schmiedebergs Arch Pharmacol. 2006. PMID: 16967291
-
Efficacy of selective 5-HT6 receptor ligands determined by monitoring 5-HT6 receptor-mediated cAMP signaling pathways.Br J Pharmacol. 2006 Aug;148(8):1133-43. doi: 10.1038/sj.bjp.0706827. Epub 2006 Jul 24. Br J Pharmacol. 2006. PMID: 16865095 Free PMC article.
-
Pharmacological onomastics: what's in a name?Br J Pharmacol. 2008 Feb;153(3):432-8. doi: 10.1038/sj.bjp.0707407. Epub 2007 Aug 13. Br J Pharmacol. 2008. PMID: 17700724 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
